Halozyme Therapeutics | HALO - Equity Capital And Reserves


Halozyme Therapeutics reported $143.54M in Equity Capital and Reserves for its fiscal quarter ending in June of 2026.





Equity Capital And Reserves Change Date
Acadia Pharmaceuticals USD 1.31B 58.54M Jun/2026
Agios Pharmaceuticals USD 1.03B 83.09M Jun/2026
Alnylam Pharmaceuticals USD 1.35B 278.74M Jun/2026
Amarin USD 443.62M 5.8M Jun/2026
Amgen USD 11.69B 2.5B Jun/2026
Baxter International USD 6.21B 163M Jun/2026
Cara Therapeutics USD 14.5M 6.44M Mar/2026
Cytokinetics USD -173.49M 653.08M Jun/2026
DBV Technologies USD 160.4M 47.5M Jun/2026
Eli Lilly USD 33.88B 2.68B Jun/2026
Halozyme Therapeutics USD 143.54M 76.09M Jun/2026
Intrexon USD 43.17M 75.33M Jun/2024
Ionis Pharmaceuticals USD 439.74M 51.68M Jun/2026
MannKind USD -67.2M 8M Jun/2026
Minerva Neurosciences USD -140.75M 106.17M Dec/2025
Nektar Therapeutics USD 576.22M 486.38M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
United Therapeutics USD 6.4B 499.2M Jun/2026
Vanda Pharmaceuticals USD 327.19M 138.81M Dec/2025